Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook

Cardinal Health reported fiscal Q1 2027 revenue of $67.5 billion, up 5%, and non-GAAP diluted EPS of $3.26, up 28% year over year. The company raised FY2027 non-GAAP EPS guidance to $12.80–$13.00 from $12.40–$12.60 and completed a $500 million share repurchase in the quarter. Pharmaceutical and Specialty Solutions profit rose 17% to $783 million, while Global Medical Products and Distribution profit fell 28% to $33 million.

Analysis

CAH’s underlying operating momentum is credible, but the EPS acceleration overstates the improvement in repeatable earnings: lower taxes and reduced share count helped, while the gap between GAAP and non-GAAP operating earnings remains material. The key test is whether Pharmaceutical and Specialty Solutions can sustain profit growth through generic economics and branded-drug pricing changes—not whether revenue continues to rise, since distribution scale carries limited incremental economics. GMPD weakness is a separate execution risk, while growth in the higher-profit “Other” businesses offers a useful mix offset if sustained.

Cash conversion deserves scrutiny: quarterly operating cash flow benefited substantially from higher payables even as receivables and inventory absorbed cash. That can reverse with purchasing cadence or supplier terms; adjusted free cash flow also excludes litigation-related cash flows. The completed repurchase supports per-share growth but is not a substitute for durable operating leverage.

Over 1–3 months, the CVS renewal’s economics and CAH’s next guidance update matter more than the announced relationship itself; verify contract duration, pricing, and volume commitments. The AdaptHealth diabetes-business acquisition may affect AHCO’s revenue mix and cash proceeds, but deal size and terms are needed before drawing a valuation conclusion. The LLY evidence study is strategically relevant but not a near-term earnings catalyst. Over 6–18 months, branded-drug pricing/regulation, generics performance, tariffs, Iran-related supply disruption, and DOJ litigation are meaningful reversal risks. Contrarian read: operating growth is better than the headline EPS quality suggests, but the guidance raise is not a clean signal of accelerating cash earnings.

Key Decisions for Investors

• CAH: favor a measured long on post-results consolidation rather than chasing the initial reaction. Reassess after the next quarter; falsify if Pharmaceutical and Specialty Solutions profit growth falls below the raised 10%–12% range or GMPD deterioration worsens without a credible recovery path.
• Track CAH cash conversion alongside earnings: a reversal in payables support, continued inventory/receivables use, or adjusted free cash flow weakening would challenge the buyback-supported EPS story. Confirm how much cash flow reflects ordinary operations versus litigation adjustments.
• Treat the CVS agreement as a catalyst to monitor, not a standalone CVS or CAH trade, until renewal terms and economics are disclosed. A binding letter of intent reduces relationship uncertainty but does not establish margin accretion.
• Keep AHCO and LLY on watch rather than trading this release: verify the AdaptHealth diabetes-business transaction size, proceeds, and closing terms, and look for evidence that the LLY study changes commercial activity before assigning earnings value.